Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,127
datasets available to search
ShareScore release 0.9.0
Dataset results
1,127 results for “cancer immunotherapy”
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
ClinicalTrials.gov study NCT00065442. IPD Sharing: Not stated. Countries: 2. Publications: 4.
Efficacy and Safety of High-Dose Rate Brachytherapy with Immunotherapy and Chemotherapy As Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT06518018. IPD Sharing: UNDECIDED. Countries: 1. Publications: 16.
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT03197467. IPD Sharing: NO. Countries: 1. Publications: 3.
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
ClinicalTrials.gov study NCT02280811. IPD Sharing: NO. Countries: 1. Publications: 3.
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
ClinicalTrials.gov study NCT02153905. IPD Sharing: NO. Countries: 1. Publications: 3.
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
ClinicalTrials.gov study NCT03338790. IPD Sharing: Not stated. Countries: 11. Publications: 2.
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
ClinicalTrials.gov study NCT01057810. IPD Sharing: Not stated. Countries: 24. Publications: 2.
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
ClinicalTrials.gov study NCT04491955. IPD Sharing: YES. Countries: 1. Publications: 1.
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
ClinicalTrials.gov study NCT00157209. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Subclonal mutational load predicts survival and response to immunotherapy in cancers with low to moderate TMB
<p>Here we provide the downloadable links of subclonal reconstruction results by <strong>CliPP</strong>, on both <strong>TCGA</strong> and <strong>PCAWG</strong> datasets. We also provide the source of our in-house simulation data (<strong>CliPPSim4k</strong>), along with a comparison between CliPP and PhyloWGS.</p> <p>For more detailed information about the data, please refer to our paper: <a href="https://www.biorxiv.org/content/10.1101/2024.07.03.601939v1" target="_new" rel="noopener">https://www.biorxiv.org/content/10.1101/2024.07.03.601939v1</a> or visit our web app: <a href="https://bioinformatics.mdanderson.org/apps/CliPP/" target="_new" rel="noopener">https://bioinformatics.mdanderson.org/apps/CliPP/</a></p>
Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance.
Open the record for dataset details and reuse information.
CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy
<p>Tumors exploit numerous immune checkpoints including those deployed by myeloid cells to curtail anti-tumor immunity. Here, we show that the C-type lectin receptor CLEC-1 expressed by myeloid cells senses dead cells killed by programmed necrosis. Moreover, we identified TRIM21 as an endogenous ligand over-expressed in various cancers. Interestingly, we observed that in mice CLEC-1 blockade combined with chemotherapy to prolong survival in tumor models. Loss of CLEC-1 reduced the accumulation of immunosuppressive myeloid cells in tumors and invigorated the activation state of dendritic cells (DCs), thereby increasing T cell responses. Mechanistically, we found that the absence of CLEC-1 increased the cross-presentation of dead-cell associated antigens by conventional type-1 DCs. Importantly, we identified anti-human CLEC-1 antagonist antibodies able to enhance anti-tumor immunity in CLEC-1 humanized mice. Altogether, our results demonstrate that CLEC-1 acts as an immune checkpoint in myeloid cells and support CLEC-1 as a novel target for cancer immunotherapy.</p>
Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer
<p>Polygenic risk score weights derived using LDpred for hypothyroidism and thyroid medication use.</p>
Simulation models for cancer immunotherapy and chemotherapy trials
<p>This repository contains code and data related to the following manuscript:</p> <p><em>In silico</em> cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome Jeroen H.A. Creemers, Kit C.B. Roes, Niven Mehra, Carl G. Figdor, I. Jolanda M. de Vries, Johannes Textor medRxiv 2021.09.09.21263319; doi: <a href="https://doi.org/10.1101/2021.09.09.21263319">https://doi.org/10.1101/2021.09.09.21263319</a></p> <p>The manuscript (the revised version of which can be found in this repository) describes three simulation models for cancer patient survival data with different immunotherapy treatments. This repository contains the source code of the simulation models, which are written in C++, as well as an R wrappers using the Rcpp package. These can be found in the directory models/TumorImmuneModels/.</p> <p>There is also a web-based implementation, written in JavaScript, available at <a href="https://computational-immunology.org/models/immunotherapy-trials/">https://computational-immunology.org/models/immunotherapy-trials/</a>.</p> <p>Finally, see the folder "figures" for the code used to perform the analyses and generate the figures shown in the manuscript.</p>
Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy
ClinicalTrials.gov study NCT03741868. IPD Sharing: NO. Countries: 1. Publications: 2.
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
ClinicalTrials.gov study NCT06486441. IPD Sharing: NO. Countries: 19. Publications: 1.
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
ClinicalTrials.gov study NCT05810402. IPD Sharing: NO. Countries: 1. Publications: 25.
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
ClinicalTrials.gov study NCT04375384. IPD Sharing: NO. Countries: 1. Publications: 1.
QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management
ClinicalTrials.gov study NCT05626764. IPD Sharing: UNDECIDED. Countries: 4. Publications: 1.
Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT04835025. IPD Sharing: UNDECIDED. Countries: 1. Publications: 13.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.